GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operatio...(testing of AIDS vaccines. Preclinical w...),Health

Date:11/6/2009

testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with an $18 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

More information is available on the Company's website at www.geovax.com.

SOURCE GeoVax Labs, Inc.

'/>"/>

SOURCE GeoVax Labs, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
2. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
3. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
4. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
5. GeoVax Reports Progress on Its AIDS Vaccine Technology
6. GeoVax Secures $10 Million Financing Commitment
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
11. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel